Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: A decision analysis

Liver Transplantation

Volumn 10, Issue 12, 2004, Pages 1468-1475

  Amin, Manish G ^a   Wolf, Michael P ^a   TenBrook Jr , John A ^a   Freeman Jr , Richard B ^a   Cheng, Steve J ^b   Pratt, Daniel S ^c   Wong, John B ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Kaiser Permanente ^*  (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CADAVER DONOR; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY ANALYSIS;

CADAVER; DECISION SUPPORT TECHNIQUES; HUMANS; LIVER TRANSPLANTATION; MARKOV CHAINS; MONTE CARLO METHOD; SURVIVAL ANALYSIS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 11144268942     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20304     Document Type: Article

References (38)

1. OPTN. Liver-only National Data 1989 -2002: Organ Procurement and Transplantation Network: Accessed June 2003.
2. Wall WJ, Mimeault R, Grant DR, Bloch M. The use of older donor livers for hepatic transplantation. Transplantation 1990; 49:377-381.
3. Adam R, Astarcioglu I, Azoulay D, Chiche L, Bao YM, Castaing D, Bismuth H. Liver transplantation from elderly donors. Transplant Proc 1993;25:1556-1557.
4. Karatzas T, Olson L, Ciancio G, Burke GW III, Spires G, Cravero L, et al. Expanded liver donor age over 60 years for hepatic transplantation. Transplant Proc 1997;29:2830-2831.
5. De Carlis L, Colella G, Sansalone CV, Aseni P, Rondinara GF, Slim AO, et al. Marginal donors in liver transplantation: the role of donor age. Transplant Proc 1999;31:397-400.
6. Agnes S, Avolio AW, Magalini SC, Grieco G, Castagneto M. Marginal donors for patients on regular waiting lists for liver transplantation. Transpl Int 1996;9 Suppl 1:S469-471.
7. Feng S, Bragg-Gresham JL, Dykstra DM, Punch JD, Greenstein SM, Merion RM. Definitions and outcomes of transplants using expanded criteria donor livers. Hepatology 2004;38 Suppl 1:S6.
8. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
9. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871.
10. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001;7:567-580.
11. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
12. Personal communication with Dr. Richard Freeman. SRTR. 30-day transplant and mortality rates after waitlisting for liver for liver-only candidates on the waitlist between 2/27/02 and 8/10/02, calculated by MELD/PELD lab score-overall. UNOS January 2003.
13. Personal communication with Dr. Richard Freeman. UNOS. Effect of MELD on RR of mortality (first 3 months posttransplant) in patients transplanted between 2/28/02 and 8/31/02. June 2003.
14. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5:157-177.
15. Onaca NN, Levy MF, Sanchez EQ, Chinnakotla S, Fasola CG, Thomas MJ, et al. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl 2003;9:117-123.
16. Briceno J, Solorzano G, Pera C. A proposal for scoring marginal liver grafts. Transpl Int 2000;13 Supp1 1:S249-S252.
17. Personal communication with Dr. Richard Freeman. UNOS. Liver Kaplan-Meier patient survival rates for transplants performed: 1996-2001; 2003.
18. Pasta DJ, Taylor JL, Henning JM. Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter pylori. Med Decis Making 1999;19:353-363.
19. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003;9:651-663.
20. Briceno J, Lopez-Cillero P, Rufian S, Diaz-Iglesias C, Solorzano G, Padillo J, et al. Impact of marginal quality donors on the outcome of liver transplantation. Transplant Proc 1997;29:477-480.
21. Grande L, Matus D, Rimola A, Manyalic M, Cabrer C, Garcia-Valdecasas JC, Visa J. Expanded liver donor age over 60 years for hepatic transplantation. Clin Transpl 1998:297-301.
22. Mor E, Klintmalm GB, Gonwa TA, Solomon H, Holman MJ, Gibbs JF, et al. The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation 1992;53:383-386.
23. Loinaz C, Gonzalez EM. Marginal donors in liver transplantation. Hepatogastroenterology 2000;47:256-263.
24. Adam R, Reynes M, Johann M, Morino M, Astarcioglu I, Kafetzis I, et al. The outcome of steatotic grafts in liver transplantation. Transplant Proc 1991;23:1538-1540.
25. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002;35:105-109.
26. Mueller AR, Platz KP, Krause P, Steinmuller T, Glanemann M, Neumann U, et al. Is the use of marginal liver grafts justified? Transplant Proc 1999;31:401-402.
27. Doyle HR, Dvorchik I, Mitchell S, Marino IR, Ebert FH, McMichael J, Fung JJ. Predicting outcomes after liver transplantation. A connectionist approach. Ann Surg 1994;219:408-415.
28. Gayowski T, Marino IR, Singh N, Doyle H, Wagener M, Fung JJ, Starzl TE. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 1998;65:499-504.
29. Gonzalez FX, Rimola A, Grande L, Antolin M, Garcia-Valdecasas JC, Fuster J, et al. Predictive factors of early postoperative graft function in human liver transplantation. Hepatology 1994; 20:565-573.
30. Markmann JF, Markmann JW, Markmann DA, Bacquerizo A, Singer J, Holt CD, et al. Preoperative factors associated with outcome and their impact on resource use in 1148 consecutive primary liver transplants. Transplantation 2001;72:1113-1122.
31. Ploeg RJ, D'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation - a multivariate analysis. Transplantation 1993;55:807-813.
32. Wong T, Devlin J, Rolando N, Heaton N, Williams R. Clinical characteristics affecting the outcome of liver retransplantation. Transplantation 1997;64:878-882.
33. Clavien PA, Harvey PR, Strasberg SM. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. Transplantation 1992;53:957-978.
34. Serracino-Inglott F, Habib NA, Mathie RT. Hepatic ischemia-reperfusion injury. Am J Surg 2001;181:160-166.
35. Wilhelm SM, Stowe NT, Robinson AV, Schulak JA. The use of the endothelin receptor antagonist, tezosentan, before or after renal ischemia protects renal function. Transplantation 2001;71: 211-216.
36. Amersi F, Farmer DG, Shaw GD, Kato H, Coito AJ, Kaldas F, et al. P-selectin glycoprotein ligand-1 (rPSGL-Ig)-mediated blockade of CD62 selectin molecules protects rat steatotic liver grafts from ischemia/reperfusion injury. Am J Transplant 2002; 2:600-608.
37. Amersi F, Buelow R, Kato H, Ke B, Coito AJ, Shen XD, et al. Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. J Clin Invest 1999;104:1631-1639.
38. Coito AJ, Buelow R, Shen XD, Amersi F, Moore C, Volk HD, et al. Heme oxygenase-1 gene transfer inhibits inducible nitric oxide synthase expression and protects genetically fat Zucker rat livers from ischemia-reperfusion injury. Transplantation 2002; 74:96-102.